Bullish & Foolish
Full SINT fundamentals All 466 on the Survival Watch

SINTSintx Technologies, Inc.

Is Sintx Technologies struggling financially?

Yes, by its own account. Sintx Technologies told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

  • Grant funding

    We have received three NIH grants to develop 3D printed silicon nitride / polymer implantable medical devices.

    Form 10-K, filed 20 Mar 2026. Read it on SEC.gov

Sector
Biotech/Pharma
Market cap
$10.3M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Oct 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$3.6M

÷

Cash burned over the last 12 months

$8.8M

What Sintx Technologies told the SEC

…cleared medical products, access to capital through the Company’s ATM program, and execution of the Armor facility sublease—management has concluded that substantial doubt remains regarding the Company’s ability to continue as a going concern for a period of at least 12 months from the date these condensed consolidated financial statements are issued. The Company’s ability to continue as a going concern will depend on its…

Sintx Technologies, Inc., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 105.6% share-count increase The company issued stock. Each share now owns 51.4% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt